Chlorphenamine/codeine

Drug Profile

Chlorphenamine/codeine

Alternative Names: Chlorpheniramine/codeine; Codeine/chlorpheniramine; LPCN 1084; Rinotuss12; Tuxarin

Latest Information Update: 03 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lipocine
  • Developer Spriaso
  • Class Antitussives; Morphinans; Opioid analgesics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Common cold; Cough

Most Recent Events

  • 22 Jun 2015 Registered for Common cold in USA (PO)
  • 22 Jun 2015 Registered for Cough in USA (PO)
  • 11 Nov 2014 Chlorphenamine/codeine is available for licensing as of 11 Nov 2014. http://spriasollc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top